2025-01-03 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Johnson & Johnson (JNJ), a global healthcare company specializing in pharmaceuticals, medical devices, and consumer health products, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return of JNJ is 21.90%, while the S&P 500's is 113.65%. This results in a substantial difference of -91.7%, placing it at the 7.1% percentile of the historical range of divergence between JNJ and the S&P 500.  The provided data shows that JNJ's performance has consistently lagged behind the broader market, indicated by a consistently negative alpha.

**2. Recent Price Movement:**

* **Closing Price:** $143.97
* **Last Market Price:** $144.03
* **5-Day Moving Average:** $144.51
* **20-Day Moving Average:** $146.22
* **60-Day Moving Average:** $154.30

The current price is below all three moving averages, suggesting a downward trend.  The relatively small difference between the closing and last market price indicates minimal recent volatility.

**3. Technical Indicators & Expected Return:**

* **RSI (41.47):**  Indicates the stock is approaching oversold territory, but not yet decisively so.
* **PPO (0.12):** A positive PPO suggests bullish momentum, although the value is relatively low.
* **Relative Strength Divergence (20-day):**  A positive change of +4.5 indicates short-term upward momentum.
* **Expected Return (-356.5%):** This extremely negative expected return relative to the S&P 500 over the long term (2+ years) is a significant concern and requires further investigation.  This likely reflects the substantial underperformance observed in the historical data. The statement needs clarification regarding its calculation and the timeframe considered.

**4. Recent Earnings Analysis:**

The provided earnings data reveals some inconsistencies and a need for clarification:  The EPS for 2023-10-27 ($10.32) is significantly higher than other quarters, indicating a potential reporting issue or exceptional event.   The Revenue remains relatively consistent between $21.35B and $22.47B throughout the reported periods.  EPS fluctuates, lacking a clear upward or downward trend, except for the outlier in October 2023.  Without further information (like earnings expectations), we cannot definitively identify beats or misses.  Data accuracy needs verification.


**5. Financial Information Analysis:**

* **Revenue:** Revenue has been relatively stable, hovering around $22B, with slight quarter-to-quarter fluctuations.  
* **Profit Margin:** Remains relatively consistent and high, between 68% and 70%, indicating strong profitability.
* **Equity:** Equity fluctuates, showing no clear trend.
* **ROE:**  The ROE is highly volatile, showing significant variation between quarters, with an exceptionally high ROE of 36.54% in 2023-09-30 requiring further explanation.  This inconsistency warrants investigation and clarification of the calculation methodology.

**6. News and Recent Issues:**

The provided data lacks information on recent earnings news (within the last 2 days), market outlook, or analyst opinions.  This crucial information is necessary for a comprehensive analysis.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the given historical period. While the company demonstrates strong profitability margins, the recent earnings data shows inconsistencies, and the long-term expected return relative to the S&P 500 is severely negative.  The technical indicators suggest a slightly oversold condition with some short-term upward momentum, but this is overshadowed by the significant long-term underperformance.  The lack of current news, market outlook, and analyst sentiment further limits the analysis.  Crucially, the data provided contains inconsistencies that need to be resolved before a robust and reliable conclusion can be drawn.  More information is needed to accurately assess the current situation and potential future performance.

**8. Recommendations:**

Given the inconsistencies in the data and the absence of crucial market information, making concrete investment recommendations is premature.  Further investigation is required to address the issues in the provided data (particularly the outlier EPS value and volatile ROE), incorporate recent market sentiment, and include analyst opinions before any informed decision-making can occur.  The extreme negative projected return should be thoroughly investigated before considering any long-term investment.
